NCT03760991 - Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of Insulin | Biotech Hunter

Enrollment

372

Participants

Timeline

Start Date

December 18, 2018

Primary Completion Date

September 23, 2020

Study Completion Date

September 23, 2020

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

INSULIN GLARGINE (U300)

"Pharmaceutical form: Solution for injection in a prefilled pen~Route of administration: Subcutaneous"

Trial Locations (14)

Investigational site Argentina, Buenos Aires

investigational site COLOMBIA, Colombia

investigational site Egypt, Egypt

investigational site HONG KONG, Hong Kong

investigational site INDIA, India

Investigational site Indonesia, Indonesia

investigational site LEBANON, Lebanon

Investigational site Malaysia, Putrajaya

Investigational site PERU, Hacienda Perú

investigational site PHILIPPINES, Philippines

Investigational site Saudi Arabia, Saudi Arabia

Investigational site South Africa, South Africa

Investigational site Thailand, Thailand

investigational site TURKEY, Turkey